[The effect of nifurtimox on intra- and extracellular development stages of Toxoplasma gonii].
D000818:Animals; D000994:Antitrichomonal Agents / Q000627:therapeutic use*; D003499:Cyclic S-Oxides / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005260:Female; D005856:Germ-Free Life; D007933:Leucomycins / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D009581:Nitrofurans / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000627:therapeutic use; D013843:Thiazines / Q000627:therapeutic use*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D000994:Antitrichomonal Agents; D003499:Cyclic S-Oxides; D004338:Drug Combinations; D007933:Leucomycins; D009581:Nitrofurans; D013843:Thiazines; D013411:Sulfadiazine
Der Einfluss von Nifurtimox auf intra- und extrazelluläre Entwicklungsstadien von Toxoplasma gondii